Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

KEYMAKER-U01 Sottostudio 01J: Uno Studio di Pembrolizumab Più MK-1084 in Partecipanti con Carcinoma Polmonare Non a Piccole Cellule (NSCLC) con Mutazioni dell'Omologo dell'Oncogene Virale del Sarcoma del Ratto di Kirsten (KRAS) G12C (MK-3475-01J/KEYMAKER-U01J)

6 novembre 2026 aggiornato da: Merck Sharp & Dohme LLC

KEYMAKER-U01 Sottostudio 01J: Uno Studio Ombrello di Fase 2 Randomizzato con Bracci a Rotazione di Agenti Sperimentali per il Trattamento di Prima Linea di Partecipanti con Carcinoma Polmonare Non a Piccole Cellule (NSCLC) Non Squamoso Avanzato o Metastatico con Mutazioni KRAS G12C

Researchers want to learn if using a study medicine called MK-1084 can help treat Non-Small Cell Lung Cancer (NSCLC). MK-1084 is a type of treatment called targeted therapy for the Kirsten rat sarcoma viral oncogene homolog (KRAS) G12C gene change. The goal of this study is to learn about the safety of MK-1084 and to learn how many people have the cancer get smaller or go away during the study treatment.

Panoramica dello studio

Tipo di studio

Interventistico

Iscrizione (Stimato)

140

Fase

  • Fase 2

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

    • Region M. de Santiago
      • Santiago, Region M. de Santiago, Chile, 7560908
        • Reclutamento
        • Centro de Oncología de Precisión ( Site 0160)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +56991612199
      • Santiago, Region M. de Santiago, Chile, 7500921
        • Reclutamento
        • Fundacion Arturo Lopez Perez ( Site 0167)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: 56224205098
      • Santiago, Region M. de Santiago, Chile, 8420383
        • Reclutamento
        • Bradfordhill ( Site 0168)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +56998744662
    • Jiangsu
      • Nanjing, Jiangsu, Cina, 210000
        • Reclutamento
        • Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School ( Site 0318)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +8602568182222
    • Jiangxi
      • Nanchang, Jiangxi, Cina, 330209
        • Reclutamento
        • The First affiliated hospital of Nanchang University (Xianghu campus) ( Site 0306)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +86 791 8631 9333
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, Cina, 200032
        • Reclutamento
        • Zhongshan Hospital Fudan University ( Site 0319)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +8615000229853
    • Sichuan
      • Chengdu, Sichuan, Cina, 610066
        • Reclutamento
        • West China Hospital, Sichuan University ( Site 0315)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +8618980602252
      • Seoul, Corea del Sud, 03722
        • Reclutamento
        • Severance Hospital Yonsei University Health System ( Site 0080)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +82222280880
    • Northern Savonia
      • Kuopio, Northern Savonia, Finlandia, 70200
        • Reclutamento
        • Kuopion Yliopistollinen Sairaala ( Site 0261)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +35817173311
    • Pohjanmaa
      • Vaasa, Pohjanmaa, Finlandia, 65130
        • Reclutamento
        • Vaasan Keskussairaala ( Site 0263)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +358405533545
    • Southwest Finland
      • Turku, Southwest Finland, Finlandia, 20520
        • Reclutamento
        • Turku University Hospital ( Site 0262)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +35823138709
    • Uusimaa
      • Helsinki, Uusimaa, Finlandia, 00290
        • Reclutamento
        • HYKS Syöpätautien klinikka ( Site 0260)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +358406682951
    • Attica
      • Athens, Attica, Grecia, 106 76
        • Reclutamento
        • Evangelismos General Hospital of Athens ( Site 0200)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +302132041631
      • Central, Hong Kong, 0000
        • Reclutamento
        • Hong Kong Integrated Oncology Centre ( Site 0232)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +85237006888
      • Hong Kong, Hong Kong
        • Reclutamento
        • Queen Mary Hospital ( Site 0230)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +85222551727
      • Kowloon, Hong Kong
        • Reclutamento
        • Hong Kong United Oncology Centre ( Site 0231)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +852 2386 8002
    • Lombardy
      • Milan, Lombardy, Italia, 20133
        • Reclutamento
        • Fondazione IRCCS Istituto Nazionale Dei Tumori ( Site 0175)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: 00390223903829
    • Overijssel
      • Deventer, Overijssel, Olanda, 7416 SE
        • Reclutamento
        • Deventer Ziekenhuis ( Site 0272)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +31570536437
    • South Holland
      • Leiden, South Holland, Olanda, 2333 ZA
        • Reclutamento
        • Leids Universitair Medisch Centrum ( Site 0273)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +31715566376
    • Masovian Voivodeship
      • Warsaw, Masovian Voivodeship, Polonia, 02-781
        • Reclutamento
        • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie ( Site 0151)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: 48 22 546 23 36
      • Seville, Spagna, 41009
        • Reclutamento
        • Hospital Universitario Virgen de la Macarena ( Site 0093)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +34 671560092
    • Florida
      • Clermont, Florida, Stati Uniti, 34711
        • Reclutamento
        • Clermont Oncology Center ( Site 0041)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: 386-538-3169
    • North Dakota
      • Fargo, North Dakota, Stati Uniti, 58102
        • Reclutamento
        • Sanford Health Roger Maris Cancer Center ( Site 0039)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: 701-234-2000
    • South Dakota
      • Sioux Falls, South Dakota, Stati Uniti, 57104
        • Reclutamento
        • Sanford Cancer Center Oncology Clinic ( Site 0038)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: 605-328-8000
    • Bangkok
      • Bangkok, Bangkok, Tailandia, 10300
        • Reclutamento
        • Bangkok Metropolitan Administration Medical College and Vajira Hospital ( Site 0351)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +6622443461
      • Bangkok, Bangkok, Tailandia, 10700
        • Reclutamento
        • Faculty of Medicine Siriraj Hospital ( Site 0350)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +6624194488-9
      • Adana, Turchia (Türkiye), 34010
        • Reclutamento
        • Koç Üniversitesi Hastanesi ( Site 0142)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: 08502508250-21251
      • Adana, Turchia (Türkiye), 1250
        • Reclutamento
        • Baskent University Dr. Turgut Noyan Research and Training Center ( Site 0141)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +905537766235
      • Ankara, Turchia (Türkiye), 6230
        • Reclutamento
        • Hacettepe Universite Hastaneleri ( Site 0140)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +90 312 305 50 00
      • Ankara, Turchia (Türkiye), 06680
        • Reclutamento
        • Liv Hospital Ankara ( Site 0146)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: 905469299990
    • Kayseri
      • Talas, Kayseri, Turchia (Türkiye), 38039
        • Reclutamento
        • Erciyes University ( Site 0145)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: 905366550924
      • Kyiv, Ucraina, 03022
        • Attivo, non reclutante
        • VISION PARTNER Medical Centre ( Site 0135)
      • Kyiv, Ucraina, 03151
        • Reclutamento
        • LLC "MEDICAL CENTER DOBROBUT-CLINIC" ( Site 0138)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +380671502987
    • Cherkasy Oblast
      • Cherkasy, Cherkasy Oblast, Ucraina, 18009
        • Reclutamento
        • COMMUNAL NONPROFIT ENTERPRISE CLINICAL CENTER OF ONCOLOGY, HEMATOLOGY, TRANSPLANTOLOGY AND PALLIATI ( Site 0139)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +380472370123
    • Dnipropetrovsk Oblast
      • Kryvyi Rih, Dnipropetrovsk Oblast, Ucraina, 50000
        • Reclutamento
        • Medical Center "Mriya Med-Service"-Clinical Research Department ( Site 0465)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +380677490687
    • Ivano-Frankivsk Oblast
      • Ivano-Frankivsk, Ivano-Frankivsk Oblast, Ucraina, 76018
        • Reclutamento
        • Communal Non-Commercial Enterprise "Prykarpatski Clinical On-Surgery department #2 ( Site 0132)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: 380978411455
    • Kirovohrad Oblast
      • Kropyvnytskyi, Kirovohrad Oblast, Ucraina, 25011
        • Reclutamento
        • Limited Liability Company Ukrainian Center of Tomotherapy-Department of Chemotherapy ( Site 0467)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +380958718674
    • Lviv Oblast
      • Lviv, Lviv Oblast, Ucraina, 79059
        • Reclutamento
        • Lviv Territorial Medical Union Multidisciplinary Clinical Hospital ( Site 0133)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +380677724757
    • Vinnytsia Oblast
      • Vinnitsya, Vinnytsia Oblast, Ucraina, 21029
        • Reclutamento
        • Communal Noncommercial Enterprise "Podillia Regional Oncolog-Cardiothoracic department ( Site 0131)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: 380953105783
    • Zakarpattia Oblast
      • Uzhhorod, Zakarpattia Oblast, Ucraina, 88000
        • Reclutamento
        • Uzhhorod Municipal Multidisciplinary Clinical Hospital of Uzhhorod City Council ( Site 0137)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +380506847086

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

The main inclusion criteria include but are not limited to the following:

  • Has histologically or cytologically confirmed diagnosis of advanced or metastatic nonsquamous Non-Small Cell Lung Cancer (NSCLC)
  • Has tumor tissue or circulating tumor deoxyribonucleic acid (ctDNA) that demonstrates the presence of Kirsten rat sarcoma viral oncogene homolog (KRAS) G12C mutations
  • Can provide an archival tumor tissue sample or newly obtained core, incisional, excisional biopsy of a tumor lesion not previously irradiated
  • Has recovered to ≤Grade 1 or baseline from any Adverse events (AEs) due to previous anticancer therapies and/or ≤Grade 2 neuropathy and/or endocrine-related AEs adequately treated with hormone replacement
  • Has well controlled human immunodeficiency virus (HIV) on antiretroviral therapy (ART) if HIV-infected
  • Has undetectable hepatitis B (HBV) viral load and have received HBV antiviral therapy for at least 4 weeks if hepatitis B surface antigen (HBsAg) positive
  • Has undetectable hepatitis C (HCV) viral load if HCV-infected

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

  • Has a diagnosis of small cell lung cancer or, for mixed tumors, presence of small cell elements
  • Has HIV-infection with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
  • Has history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing
  • Has active inflammatory bowel disease requiring immunosuppressive medication or previous clear history of inflammatory bowel disease
  • Has uncontrolled, clinically significant cardiovascular disease or cerebrovascular disease, including New York Heart Association Class III or IV congestive heart failure, unstable angina, myocardial infarction, uncontrolled symptomatic arrhythmia, prolongation of corrected QT interval corrected for heart rate by Fridericia's formula (QTcF) interval to >470 ms, and/or other serious cardiovascular and cerebrovascular diseases within the 6 months preceding study intervention
  • Has received prior systemic anticancer therapy for advanced or metastatic NSCLC
  • Has received any prior immunotherapy and was discontinued from that treatment due to a Grade 3 or higher immune-related adverse event (irAE) (except endocrine disorders that can be treated with replacement therapy) or was discontinued from that treatment due to Grade 2 myocarditis or recurrent Grade 2 pneumonitis
  • Has received previous treatment with an agent targeting KRAS
  • Has received prior systemic anticancer therapy within 4 weeks or 5 half-lives (whichever is shorter) and has not recovered to grade ≤ 1 or baseline from AE associated with anticancer therapy before allocation/randomization
  • Has received radiation therapy to the lung that is >30 Gray within 6 months of start of study intervention
  • Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study intervention
  • Has a known additional malignancy that is progressing or has required active treatment within the past 3 years
  • Has a known active central nervous system (CNS) metastases and/or carcinomatous meningitis
  • Has an active autoimmune disease that has required systemic treatment in the past 2 years. Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid) is allowed
  • Has a history of (noninfectious) pneumonitis/interstitial lung disease (ILD) that required steroids, has current pneumonitis/ILD, or has suspected ILD or pneumonitis that cannot be ruled out by standard diagnostic assessments at screening
  • Has a history of stem cell/solid organ transplant
  • Has not adequately recovered from major surgery or has ongoing surgical complications

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Separare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Arm A- Pembrolizumab + MK-1084

Participants receive 400 mg of Pembrolizumab every 6 weeks and MK-1084 dose regimen.

Oral Administration

Intravenous administration

Altri nomi:
  • Chiavetruda
  • MK-3475
Sperimentale: Arm B- Pembrolizumab + MK-1084 + Cetuximab

Participants receive 400 mg of Pembrolizumab every 6 weeks, MK-1084 dose regimen, and Cetuximab 500 mg/m^2 every 2 weeks.

Intravenous administration

Oral Administration

Intravenous administration

Altri nomi:
  • Chiavetruda
  • MK-3475
Sperimentale: Arm C- Pembrolizumab + MK-1084 + sacituzumab tirumotecan (sac-TMT)

Participants receive 400 mg of Pembrolizumab every 6 weeks, MK-1084 dose regimen, and 4 mg/kg sacituzumab tirumotecan (sac-TMT) every 2 weeks.

Oral Administration

Intravenous administration

Altri nomi:
  • Chiavetruda
  • MK-3475

Injection powder for intravenous infusion

Altri nomi:
  • SKB264
  • MK-2870

Participants receive the following rescue medications, per approved product label, as premedication to study treatment to prevent hypersensitivity and/or infusion reactions: diphenhydramine (or equivalent histamine-1 [Hl] receptor antagonist), H2 receptor antagonist, acetaminophen or equivalent, dexamethasone or equivalent infusion, and granulocyte colony-stimulating factor (G-CSF). A steroid mouthwash (dexamethasone or equivalent) will be given as prophylaxis for stomatitis/oral mucositis.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Percentage of Participants with a Dose Limiting Toxicity (DLT)
Lasso di tempo: Up to approximately 21 days

A DLT is defined as the occurrence of protocol-specified toxicities if assessed by the investigator to be possibly, probably, or definitely related to study intervention administration, excluding toxicities clearly not related to the drug.

Up to approximately 21 days
Percentage of Participants who Experience at Least One Adverse Event (AE)
Lasso di tempo: Up to approximately 84 months

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.

Up to approximately 84 months
Percentage of Participants who Discontinue Study Intervention Due to an AE
Lasso di tempo: Up to approximately 84 months

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.

Up to approximately 84 months
Objective Response Rate (ORR) per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 as assessed by Blinded Independent Central Review (BICR)
Lasso di tempo: Up to approximately 84 months

ORR is defined as the percentage of participants with Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. The percentage of participants who experience CR or PR as assessed by BICR will be presented.

Up to approximately 84 months

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Duration of Response (DOR) per RECIST 1.1 as assessed by BICR
Lasso di tempo: Up to approximately 84 months

For participants who demonstrate a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR is defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. DOR as assessed by BICR will be presented.

Up to approximately 84 months
Progression Free Survival (PFS) per RECIST 1.1 as assessed by BICR
Lasso di tempo: Up to approximately 84 months

PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first as assessed by Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1). PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS as assessed by BICR will be presented.

Up to approximately 84 months
Overall Survival (OS)
Lasso di tempo: Up to approximately 84 months

OS, defined as the time from first dose or randomization (depending on study period) to death due to any cause. OS will be presented.

Up to approximately 84 months
Area Under the Concentration-Time Curve (AUC) for MK-1084
Lasso di tempo: At designated timepoints (up to approximately 44 days)

Blood samples will be collected to determine the AUC of MK-1084.

At designated timepoints (up to approximately 44 days)
Maximum Concentration (Cmax) of MK-1084
Lasso di tempo: At designated timepoints (up to approximately 44 days)

Blood samples will be collected to estimate Cmax of MK-1084.

At designated timepoints (up to approximately 44 days)
Trough Concentration (Ctrough) of MK-1084
Lasso di tempo: At designated timepoints (up to approximately 84 months)

Blood samples will be collected to determine the Ctrough of MK-1084.

At designated timepoints (up to approximately 84 months)

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Direttore dello studio: Medical Director, Merck Sharp & Dohme LLC

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

19 dicembre 2025

Completamento primario (Stimato)

15 novembre 2029

Completamento dello studio (Stimato)

31 maggio 2032

Date di iscrizione allo studio

Primo inviato

20 novembre 2025

Primo inviato che soddisfa i criteri di controllo qualità

20 novembre 2025

Primo Inserito (Effettivo)

28 novembre 2025

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

10 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

6 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi